



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
-----------------	-------------	----------------------	---------------------	------------------

10/590,634

05/17/2007

Bjarne Larsen

66123US(300586)

2264

21874

7590

08/18/2009

EDWARDS ANGELL PALMER & DODGE LLP

P.O. BOX 55874

BOSTON, MA 02205

EXAMINER

MOHAMED, ABDEL A

ART UNIT

PAPER NUMBER

1654

MAIL DATE

DELIVERY MODE

08/18/2009

PAPER

Please find below and/or attached an Office communication concerning this application or proceeding.

The time period for reply, if any, is set in the attached communication.

The amendment filed 08/23/06 is acknowledged, entered and considered. In view of Applicant's request claims 1-75 have been canceled and claims 76-92 have been added. Claims 76-92 are now pending in the application.

ELECTION/RESTRICTION

Restriction is required under 35 U.S.C. 121 and 372.

This application contains the following inventions or groups of inventions, which are not so linked as to form a single general inventive concept under PCT Rule 13.1.

In accordance with 37 CFR 1.499, applicant is required, in reply to this action, to elect a single invention to which the claims must be restricted.

Independent claim 76 and claims depending thereof (i.e., claims 77-91) are drawn to a PPY peptides varying in structures as noted by the selection of any amino acid substitution at any of the amino acid residues in SEQ ID NO:2, and independent claim 92 is directed to the use of the known PYY peptides for the claimed process.

The inventions listed do not relate to a single general inventive concept under PCT Rule 13.1 because, under PCT Rule 13.2, they lack the same or corresponding special technical features for the following reasons: Claims 76 and 92 read on tens of thousands of peptide sequences that are not related in structure, and therefore these claims are considered to comprise an improper Markush group. These claims are not proper linking claims because they, in fact, comprise multitudes of sequences. The peptides claimed lack unity because the peptides claimed are unrelated in structure and therefore lack a special technical feature that would unify the peptides recited in claims 76 or 92.

Therefore, the sequences are patentably distinct because they are unrelated sequences and each unrelated sequence is considered a separate and distinct product. For an elected invention drawn to either amino acid or polypeptide sequences, the Applicant must elect a **single** peptide sequence (See MPEP 803.04). Due to the increasing large size of sequence databases which must be searched and the increasing numbers of applications requiring sequence searches, it creates an undue burden on the Office to search more than a single sequence (product) per application. For these reasons, the requirement of 37 CFR 1.141 *et seq.* is no longer waived and Applicant is required to elect a **single** sequence for examination. Applicant is reminded that this is a **restriction requirement, not an election of species, but an election of a single invention**. If Applicant believes that the sequences are so overlapping as to be obvious variants of each other, Applicant may choose sequence for search, this sequence being a representative sequence of all sequences or a designated subset of the sequences, as Applicant may choose. If Applicant presents a single sequence to represent all sequences claimed, it will be understood that if this sequence or any sequence is found, the remaining sequences will be considered to be obvious variants of the found sequence.

Applicant is reminded that upon the cancellation of claims to a non-elected invention, the inventorship must be amended in compliance with 37 CFR 1.48(b) if one or more of the currently named inventors is no longer an inventor of at least one claim

Art Unit: 1654

remaining in the application. Any amendment of inventorship must be accompanied by a request under 37 CFR 1.48(b) and by the fee required under 37 CFR 1.17(i).

Applicant is advised that the reply to this requirement to be complete must include an election of the invention to be examined even though the requirement be traversed (37 CFR 1.143).

CONCLUSION AND FUTURE CORRESPONDANCE

Claims 76-92 are subject to restriction and/or election requirement.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Abdel A. Mohamed whose telephone number is (571) 272-0955. The examiner can normally be reached on First Friday off.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Cecilia Tsang can be reached on (571) 272-0562. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Art Unit: 1654

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see <http://pair-direct.uspto.gov>. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative or access to the automated information system, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.

Mohamed/A. A. M./
Examiner, Art Unit 1654

/JON P WEBER/
Supervisory Patent Examiner, Art Unit 1657